Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
LHF-535 (LHF535) is a novel and potent antiviral agent with EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
ln Vitro |
LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP).Strong antiviral activity is shown by LHF-535 against a variety of hemorrhagic fever arenaviruses. With an IC50 of 0.1-0.3 nM, LHF-535 inhibits Lassa GP-pseudotyped lentivirus[2].
|
---|---|
ln Vivo |
LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) significantly lowers viral titers in plasma, spleen, and liver while shielding mice against a deadly Tacaribe virus challenge.Delaying the first dose of LHF-535 (10 mg/kg) by 1, 2, or 3 days after infection also results in an increase in survival, indicating the effectiveness of LHF-535 as a post-exposure therapeutic in mice[2].
|
Animal Protocol |
Animal Model: IFN-α/β and-γ receptor-deficient AG129 mice[2]
Dosage: 3, 10, or 30 mg/kg/day Administration: Orally; daily; 14 days Result: Effective as a post-exposure therapeutic. |
References |
Molecular Formula |
C27H28N2O2
|
---|---|
Molecular Weight |
412.523427009583
|
Exact Mass |
412.22
|
Elemental Analysis |
C, 78.61; H, 6.84; N, 6.79; O, 7.76
|
CAS # |
1450929-77-7
|
Related CAS # |
(E)-LHF-535
|
Appearance |
Solid powder
|
SMILES |
CC(O)(C1=CC=C(/C=C\C2=CC=C3N(C4=CC=C(OC(C)C)C=C4)C=NC3=C2)C=C1)C
|
InChi Key |
DBNZTRPIBJSUIX-WAYWQWQTSA-N
|
InChi Code |
InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-
|
Chemical Name |
(Z)-2-(4-(2-(1-(4-Isopropoxyphenyl)-1H-benzo[d]imidazol-5-yl)vinyl)phenyl)propan-2-ol
|
Synonyms |
LHF535; LHF 535; LHF-535
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~150 mg/mL (~363.62 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.42 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 24.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.42 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 24.2 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4241 mL | 12.1206 mL | 24.2412 mL | |
5 mM | 0.4848 mL | 2.4241 mL | 4.8482 mL | |
10 mM | 0.2424 mL | 1.2121 mL | 2.4241 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The Lassa virus LP strain contains two unique amino acid substitutions in the transmembrane domain of the GP2 subunit.[2].PLoS Pathog. 2018 Dec 21;14(12):e1007439. td> |
LHF-535 protects AG129 mice against lethal Tacaribe virus challenge.[2].PLoS Pathog. 2018 Dec 21;14(12):e1007439. td> |
LHF-535 is effective as a post-exposure therapeutic in mice.[2].PLoS Pathog. 2018 Dec 21;14(12):e1007439. td> |
The LHF-535-resistant Tacaribe virus variant F425L is attenuated in AG129 mice and protects against subsequent challenge with the virulent wild-type virus.[2].PLoS Pathog. 2018 Dec 21;14(12):e1007439. td> |